When you look back at past 10K filings, they have been released within days of the deadline. What stands out to me about this year’s 10K, is that it was released unusually late. They literally waited until the last hour to release it.
We all knew that 2018 revenue would be several times over 2017 revenue, but we also know that 2019 Q1 revenue will be our first look into CANB’s SAM revenue - the real power behind Canbiola’s potential.
For investors (and even traders), the 2018 10K was pretty highly anticipated, and I think the recent trading volume confirms that interest. In comparison, however, the 2019 Q1 10Q is EXTREMELY anticipated because everyone knows that 2019 Q1 is the first quarter with all of the wheels turning and working together.
My theory is this:
Canbiola likely held onto the 10K for so long so that they could release it as close as possible to the 2019 Q1 10Q, for maximum effect.
As a result, I expect to see the momentum from the 10K build a solid springboard for us moving into May. Assuming the 10Q is released without delay, it will be the single most important catalyst for CANB this year - likely resulting in new highs.
Another element to consider as we move into May, is that we’ve now seen our second CVSI-like run in the CBD sector (as far as I’m aware). Most recall CV Sciences’ run from $.40 to nearly $3.00. If not, they certainly remember last year’s run up to $9.00.
In similar fashion, we just watched
CBD Unlimited ($EDXC) run from $.04 to $.75 in the last few weeks. What’s more, their run doesn’t seem to be slowing down, and they look well positioned to exceed CVSI’s gains last year.
When several companies boast these sorts of gains, all it does is draw more attention to the sector. At this point, it seems clear that we are moving into heavy mania territory. Investors and traders alike are looking for the next CVSI, the next EDXC - the next 2,000% gainer.
People who missed the CVSI opportunity, along with those that missed the EDXC opportunity, aren’t going to let the next undervalued company pass them by. To that end, Canbiola is one of the most undervalued CBD companies that brings in serious revenue.
Altogether, I think the momentum we build from the 2018 10K, along with the anticipation we see for the 2019 Q1 10Q, and manic buying we’re seeing in other CBD companies, is going to set Canbiola up to be one of the few 2,000+ gainers this year.
